Thomas Muenzel

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes

Veikko Salomaa, Aki S. Havulinna, Olli Saarela et al. · PLoS ONE · 2010 · 173 citations · Full text

Public Health, Biostatistics, Epidemiologic Methods +14

Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association

Janina Stępińska, M. Lettino, Ingo Ahrens et al. · European Heart Journal Acute Cardiovascular Care · 2020 · 158 citations · Full text

Medicine, Cardiology, Emergency Medicine +17

Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation

Ellen Hoffmann, Florian Straube, Karl Wegscheider et al. · EP Europace · 2019 · 128 citations · Full text

Medicine, Cardiology, Interventional Cardiology +12

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17